Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Investing Activities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cash from Investing Activities for 15 consecutive years, with -$52.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 22.55% year-over-year to -$52.9 million, compared with a TTM value of -$264.4 million through Dec 2025, down 108.52%, and an annual FY2025 reading of -$264.4 million, down 108.52% over the prior year.
  • Cash from Investing Activities was -$52.9 million for Q4 2025 at Neurocrine Biosciences, up from -$196.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $63.1 million in Q1 2021 and bottomed at -$201.8 million in Q4 2023.
  • Average Cash from Investing Activities over 4 years is -$61.2 million, with a median of -$52.9 million recorded in 2025.
  • Peak annual rise in Cash from Investing Activities hit 125.82% in 2025, while the deepest fall reached 896.36% in 2025.
  • Year by year, Cash from Investing Activities stood at $63.1 million in 2021, then plummeted by 419.81% to -$201.8 million in 2023, then skyrocketed by 66.15% to -$68.3 million in 2024, then rose by 22.55% to -$52.9 million in 2025.
  • Business Quant data shows Cash from Investing Activities for NBIX at -$52.9 million in Q4 2025, -$196.7 million in Q3 2025, and -$29.0 million in Q2 2025.